Abstract
New effective hypotensive agents have been recently introduced into clinical practice, but often more than one drug has to be used to prevent further visual field loss. The aim of this study was to evaluate the intraocular pressure (IOP)-lowering efficacy and safety of bimatoprost 0.03% compared with the association of timolol 0.5% and latanoprost 0.005% in open-angle glaucoma patients. In this 6-month, prospective, parallel, randomised, investigator-masked clinical trial, 61 glaucomatous patients treated with timolol 0.5% twice in both eyes were enrolled. The timolol 0.5% was replaced by bimatoprost 0.03% once daily (group I) or by latanoprost 0.005% plus timolol 0.5% (group II). IOP measurements were performed at the baseline visit and at days 15, 30, 60, 90, 120 and 180. Digital colour photography was used to evaluate topical side effects. Fifty-six of the 61 patients were included for the intent-to-treat analysis (28 in group I and 28 in group II). Baseline mean IOP was similar in the two groups (p=0.5). Both treatments lowered the mean IOP at every visit significantly compared with the baseline (p<0.01). Comparing the IOP reductions obtained by the two treatments, no significant differences were found at any time during th...Continue Reading
References
Sep 1, 1992·International Ophthalmology·M BatterburyD Wong
Oct 21, 1998·American Journal of Ophthalmology
Oct 12, 2000·American Journal of Ophthalmology
Feb 13, 2001·American Journal of Ophthalmology·R F BrubakerA M Vandenburgh
Apr 25, 2001·Clinical Therapeutics·A SheddenUNKNOWN Timoptic-XE 0.5% Study Group
May 31, 2001·Ophthalmology·J D BrandtUNKNOWN Bimatoprost Study Group
Jun 13, 2001·Acta Ophthalmologica Scandinavica·A M BronM Johansson
Jul 4, 2001·Survey of Ophthalmology·R F Brubaker
Jul 4, 2001·Survey of Ophthalmology·M SherwoodUNKNOWN Bimatoprost Study Groups 1 and 2
Jul 27, 2001·Archives of Ophthalmology·R A LaibovitzJ Cheetham
Jul 24, 2001·The British Journal of Ophthalmology·W Y ZhangA Azuara-Blanco
Sep 27, 2001·Advances in Therapy·S GandolfiUNKNOWN Bimatoprost Study Group 3
Dec 13, 2001·European Journal of Pharmacology·N A SharifC R Kelly
Mar 27, 2002·The British Journal of Ophthalmology·P J PisellaC Baudouin
Apr 3, 2002·Ophthalmology·Carl B Camras
May 31, 2002·American Journal of Ophthalmology·Daniel J O'ConnorAlden Mead
Jun 7, 2002·Archives of Ophthalmology·Mae O GordonMichael A Kass
Sep 3, 2002·Survey of Ophthalmology·Joern B Soltau, Thom J Zimmerman
Oct 9, 2002·Archives of Ophthalmology·Anders HeijlUNKNOWN Early Manifest Glaucoma Trial Group
Oct 9, 2002·Archives of Ophthalmology·Eve J HigginbothamUNKNOWN Bimatoprost Study Groups 1 and 2
Oct 9, 2002·Archives of Ophthalmology·Paul R Lichter
Nov 9, 2002·Canadian Journal of Ophthalmology. Journal Canadien D'ophtalmologie·Masahiko SugimotoYukitaka Uji
Nov 14, 2002·American Journal of Ophthalmology·Paul J Lama
Dec 31, 2002·American Journal of Ophthalmology·Robert S NoeckerUNKNOWN Bimatoprost/Latanoprost Study Group
Citations
Oct 6, 2012·Eye·K InoueG Tomita
Aug 7, 2010·Clinical Ophthalmology·Anne J Lee, Peter McCluskey
Jan 26, 2012·Clinical Ophthalmology·Kenji InoueGoji Tomita
Dec 18, 2009·Current Medical Research and Opinion·M OrmeJ Loftus
Jan 2, 2008·Ophthalmology·Anastasios G P KonstasWilliam C Stewart
Jun 10, 2008·Acta Ophthalmologica·Christophe Baudouin
Mar 30, 2010·The British Journal of Dermatology·M TauchiE Lütjen-Drecoll
Nov 26, 2005·Current Medical Research and Opinion·Stefan HolmstromMark Aagren
Feb 22, 2014·Ophthalmology and Eye Diseases·Yoshimi NiwanoMasahiko Ayaki
Nov 26, 2009·Drugs & Aging·Monique P Curran
Apr 14, 2016·The Open Ophthalmology Journal·Mitsuhiro ImasawaKenji Kashiwagi
Aug 29, 2019·Expert Opinion on Therapeutic Targets·Alain P VasserotNeil J Poloso
Dec 18, 2021·Journal of the European Academy of Dermatology and Venereology : JEADV·D M HutchisonN A Mesinkovska